Craig-Hallum lowered the firm’s price target on Natera to $117 from $121 and keeps a Buy rating on the shares. Natera’s Q1 results were consistent with the firm’s thesis that the company has a huge runway for growth with potential upside to numbers, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
- TipRanks’ ‘Perfect 10’ List: Analysts See Opportunity in These 2 Top-Scoring Stocks
- Natera announces publication of dd-cfDNA study data
- Natera assumed with a Buy at Craig-Hallum
- Natera announces new data from two studies on Prospera Heart dd-cfDNA test
